ANZCTR search results

People with severe mental illnesses like schizophrenia or bipolar disorder do not often receive the best care for heart disease. This contributes to a 20-year reduction in life expectancy. In this study we will work alongside General Practitioners to check the heart health of 504 people aged between 35 and 74 diagnosed with a severe mental illness. People randomly allocated to the intervention group will work with a research nurse to set pharmacological and non-pharmacological treatment goals tailored to their individual risk factors with general practitioner involvement. This will be followed by 12 months of focused support. People allocated to the active control group will receive general heart health information, a recommendation follow up with their general practitioner and monthly contact from a research team member. We hope the intervention leads to a reduction in the 5-year absolute cardiovascular disease risk compared to the active control group.

This project aims to test the appeal, feasibility and effects on eating behaviours of a scalable, evidence-based, web- and phone-delivered healthy eating program for socioeconomically disadvantaged adults with Type 2 diabetes. The project also aims to test the effects of the program on food-related skills and attitudes, including self-efficacy and perceived barriers to selecting and preparing a balanced healthy diet. Sixty adults with Type 2 diabetes, and who hold a health care card or pension (indicators of socioeconomic disadvantage), will be recruited, with 40 expected to complete the program and evaluations (conservatively assuming up to 33% drop-out). Participants will receive a 12-week, skills-based behaviour change program, aimed at increasing healthy eating skills, attitudes and behaviours. It is based on an evidence-based behaviour change program developed by the investigators, and delivered using 6 website modules and 36 SMS text messages. Effects on eating behaviours and attitudes will be assessed at baseline, immediately after the intervention (week 12), and six months (26 weeks) later (ie, at 12 and 38 weeks post-baseline). We will also assess participants' perceptions of the program (process evaluation) at weeks 12 and 38.

Potential participants will be identified from an existing database of knee surgery with ethical approval. If the sport of injury is undocumented then the participants medical record will be reviewed, which is within the parameters of the approved database. Participants will be contacted via email where possible and invited to complete the questionnaire online, using RedCap questionnaire which is hosted on a secure medical server at St Vincent’s Hospital. The questionnaire should take less than 5 minutes to complete. Participants who are unable or unwilling to complete the questionnaire online will be invited to complete a paper copy of the questionnaire, which can be posted to them and include a reply paid envelope. The questionnaire will consist of the ACL RSI scale, which is a disease specific, reliable and validated questionnaire for ACL injuries. Participants will also be asked if they have made a return to sport, whether any of their direct family members have had ACL injuries, and if they have sustained any further injuries to their knees. Results will be grouped according to sport of primary injury to determine the incidence of reinjury and return to sport across sporting populations.

Intraocular lens technology has significantly developed over time to include multifocal and trifocal options. The motivated patient can now readily achieve optical independence for most circumstances. Previously, Alcon have provided the Panoptix Presbyopia Correcting IOL in spherical form only. Residual astigmatism has been shown to decrease unaided visual acuity. As approximately 40% of patients will have corneal astigmatism of 0.75D or greater, this represents a significant cohort of patients that may not adequately benefit from the Panoptix IOL in its current format. (Teresa JCRS 2009) The introduction of a toric option presents a positive opportunity for these patients to optimize their unaided vision at all distances. The objective of this study is to describe the visual outcomes and safety at minimum 6 months (180 days) post bilateral implantation of the Panoptix Toric IOL. Subject information will be drawn from a single study visit however preoperative and prior surgical information will be collated also.

Sales of wearable technology have grown exponentially over the last few years. The latest generation devices promise the ability to diagnose a common abnormal rhythm, atrial fibrillation (AF) which is a leading cause of stroke. However, data on the accuracy of these diagnoses has not been validated in clinical trials. Our study aims to assess the accuracy of 2 commercially available smart watches for diagnosing AF compared to the gold standard 12 lead ECG. 200 participants will be recruited from the cardiology outpatient clinic. Those over 65 years of age will be included. Exclusion criteria will be: Participants <65 years, unable to provide consent, presence of pacemaker, non-ambulatory participants and those unable to record an ECG on the smart watch (eg. tremor, arthritis). Recordings will be taken from each watch and a 12 lead ECG acquired during the same session. The accuracy of each watch for diagnosing AF and sinus rhythm will be compared to the 12 lead ECG. A brief survey will also be given to each participant. Baseline characteristics including cardiovascular risk factors, history of arrhythmia's and medication use will be noted.

This study is designed to measure the risk factors that are important in the development of muscle relaxant anaphylaxis. It does this by comparing risk factors between two similar groups of patients that have had anaphylaxis, the only difference being that one group suffered anaphylaxis to a muscle relaxant, the other to cephazolin.

The purpose of this trial is to investigate the effects of nocturnal IHL-42X on apnoea hypopnea index, sleep quality and mood in healthy adults. This will be a 6- week, double-blind, placebo controlled randomised trial in patients with suspected or diagnosed mild to moderate Obstructive Sleep Apnoea (OSA) with 3 visits in total (V0, V1 and V2). It is hypothesised that the active treatment will reduce AHI, improve mood and improve well-being after 6 weeks supplementation compared to placebo.

This study is a two-part longitudinal, observational study. Part 1 of the study will be a cross-sectional analysis ofroutinely collected data from the Prince of Wales hospital falls, balance and bone health clinic (1st of February 2019 - 31st of July, 2021) to proivde a descriptive analysis of attendees. Part 2 of the study will involve a follow-up questionnaire completed via telephone by patients that consent to be involved in this element of the study six to nine months after their clinic appointment date to gain isight into the uptake of clinic recommendations. It is hypothesised that patients that have a positive attitude and intention towards falls prevention recommended by health professionals will be more likely to participate in such recommendations. Also patients that participate in multi-component recommendations (e.g. Stepping On falls prevention program) will have greater improvements in outcomes (e.g. number of falls, fear of falling) compared to patients in single component recommendations (e.g. medication review).

Title Autologous Protein Solution (APS) – the Biological symptom management of HIP osteoarthritis. The hypothesis of this study is that a single injection of APS (nSTRIDE, Zimmer Biomet USA) a product derived from the participant's own blood, is safe and leads to a reduction in hip pain and an improvement in hip function at 3 months which is sustained at 12 months. This will be tested in 10 participants aged over 40 years with painful hip osteoarthritis and mild to moderately severe structural change on x-rays.

A dietary intervention trial will be conducted in cognitively healthy subjects in sequential design. The trial will involve the consumption of increasing doses of a medium-chain triglyceride oil. Each dose will be consumed for 1 week and at the end of each dose period participants will donate blood samples, complete questionnaires and neuropsychological tests and have their anthropometric measurements and blood pressure taken. In addition, participants will complete a 3-day food records every week.